A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study tests whether adding a new oral drug called alintegimod (7HP349) to a standard immunotherapy combination (ipilimumab and nivolumab) can improve outcomes for people with advanced solid tumors like melanoma, lung cancer, liver cancer, and others. **You may be eligible if...** - You are 18 or older - You have a confirmed advanced or metastatic solid tumor (including melanoma, kidney cancer, liver cancer, mesothelioma, certain colon cancers, or lung cancer without certain genetic mutations) - Your cancer has returned or progressed despite prior treatment - You are in good enough physical condition to tolerate treatment (ECOG performance status 0 or 1) - You have adequate kidney, liver, and blood function - Your life expectancy is more than 12 weeks **You may NOT be eligible if...** - You have serious unresolved side effects from prior cancer treatment - You have active autoimmune conditions requiring systemic treatment - You are pregnant or unwilling to use contraception Talk to your doctor to see if this trial is right for you.